Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

<< Previous

Bullboard Posts

Next >>

Comment by PitchinPennieson Feb 26, 2021 3:01pm

127 Views

Post# 32673197

RE:RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

Fantastic exercise in hair-splitting from Mr. Paid Claque. Craig will read it and gladly slip another $12.50 in your tip jar, so the pizza's on Cipher tonight. As for those of us who did pay $15 per share in the belief that this company might be going somewhere, you are quite correct to categorize us as "haters." Speaking for myself, I do hate it when morons mess up what might have been a good thing. Our friend, Mr. Paid Claque, seems to have all the patience in the world for Craig. Wonder why?

<< Previous

Bullboard Posts

Next >>

Three stocks with strong income statements to buy right now